Abbott India [ABBOTINDIA] vs Pfizer [PFIZER] Detailed Stock Comparison
Abbott India
NSE
Loading...
Pfizer
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Abbott India wins in 10 metrics, Pfizer wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Abbott India | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 46.44 | 29.68 | Pfizer |
| Price-to-Book Ratio | 15.91 | 5.69 | Pfizer |
| Debt-to-Equity Ratio | 4.65 | 2.57 | Pfizer |
| PEG Ratio | 4.03 | 1.09 | Pfizer |
| EV/EBITDA | 37.93 | 28.90 | Pfizer |
| Profit Margin (TTM) | 22.04% | 34.83% | Pfizer |
| Operating Margin (TTM) | 24.51% | 32.44% | Pfizer |
| EBITDA Margin (TTM) | 24.51% | 32.44% | Pfizer |
| Return on Equity | 33.41% | 18.20% | Abbott India |
| Return on Assets (TTM) | 23.90% | 15.63% | Abbott India |
| Free Cash Flow (TTM) | $9.59B | $6.32B | Abbott India |
| Dividend Yield | 1.41% | 1.27% | Abbott India |
| 1-Year Return | 4.24% | -14.79% | Abbott India |
| Price-to-Sales Ratio (TTM) | 10.23 | 10.35 | Abbott India |
| Enterprise Value | $648.37B | $213.39B | Abbott India |
| EV/Revenue Ratio | 9.84 | 9.19 | Pfizer |
| Gross Profit Margin (TTM) | 45.80% | 64.97% | Pfizer |
| Revenue per Share (TTM) | $3,101 | $507 | Abbott India |
| Earnings per Share (Diluted) | $682.34 | $176.89 | Abbott India |
| Beta (Stock Volatility) | 0.09 | 0.13 | Abbott India |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Abbott India vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Abbott India | 0.02% | -3.55% | -4.32% | 4.50% | 3.55% | 4.85% |
| Pfizer | -0.23% | -8.64% | -2.09% | -5.83% | 28.11% | -2.22% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Abbott India | 4.24% | 70.67% | 90.27% | 503.72% | 2,685.27% | 11,572.54% |
| Pfizer | -14.79% | 21.34% | 8.24% | 123.32% | 367.35% | 547.13% |
Performance & Financial Health Analysis: Abbott India vs Pfizer
| Metric | ABBOTINDIA | PFIZER |
|---|---|---|
| Market Information | ||
| Market Cap | ₹674.33B | ₹240.18B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 8,575 | 113,572 |
| 90 Day Avg. Volume | 6,827 | 50,263 |
| Last Close | ₹31,480.00 | ₹5,156.00 |
| 52 Week Range | ₹25,325.00 - ₹37,000.00 | ₹3,701.00 - ₹6,451.15 |
| % from 52W High | -14.92% | -20.08% |
| All-Time High | ₹37,000.00 (Jun 27, 2025) | ₹6,451.15 (Sep 02, 2024) |
| % from All-Time High | -14.92% | -20.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.12% | 0.07% |
| Quarterly Earnings Growth | 0.12% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.35% |
| Operating Margin (TTM) | 0.25% | 0.32% |
| Return on Equity (TTM) | 0.33% | 0.18% |
| Debt to Equity (MRQ) | 4.65 | 2.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1,992.14 | ₹921.88 |
| Cash per Share (MRQ) | ₹1,465.07 | ₹608.26 |
| Operating Cash Flow (TTM) | ₹13.36B | ₹9.08B |
| Levered Free Cash Flow (TTM) | ₹14.14B | ₹7.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.41% | 1.27% |
| Last 12-Month Dividend | ₹475.00 | ₹70.00 |
Valuation & Enterprise Metrics Analysis: Abbott India vs Pfizer
| Metric | ABBOTINDIA | PFIZER |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 46.44 | 29.68 |
| Forward P/E | 37.41 | 31.36 |
| PEG Ratio | 4.03 | 1.09 |
| Price to Sales (TTM) | 10.23 | 10.35 |
| Price to Book (MRQ) | 15.91 | 5.69 |
| Market Capitalization | ||
| Market Capitalization | ₹674.33B | ₹240.18B |
| Enterprise Value | ₹648.37B | ₹213.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.84 | 9.19 |
| Enterprise to EBITDA | 37.93 | 28.90 |
| Risk & Other Metrics | ||
| Beta | 0.09 | 0.13 |
| Book Value per Share (MRQ) | ₹1,992.14 | ₹921.88 |
Financial Statements Comparison: Abbott India vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABBOTINDIA | PFIZER |
|---|---|---|
| Revenue/Sales | ₹17.38B | ₹6.03B |
| Cost of Goods Sold | ₹9.42B | ₹2.11B |
| Gross Profit | ₹7.96B | ₹3.92B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹4.26B | ₹1.96B |
| EBITDA | ₹5.18B | ₹2.77B |
| Pre-Tax Income | ₹4.93B | ₹2.60B |
| Income Tax | ₹1.27B | ₹677.80M |
| Net Income (Profit) | ₹3.66B | ₹1.92B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABBOTINDIA | PFIZER |
|---|---|---|
| Cash & Equivalents | ₹5.61B | ₹4.95B |
| Total Current Assets | ₹47.65B | ₹35.13B |
| Total Current Liabilities | ₹14.07B | ₹5.70B |
| Long-Term Debt | ₹1.58B | ₹676.20M |
| Total Shareholders Equity | ₹42.33B | ₹42.17B |
| Retained Earnings | ₹32.21B | ₹24.36B |
| Property, Plant & Equipment | ₹3.30B | ₹1.72B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABBOTINDIA | PFIZER |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ABBOTINDIA | PFIZER |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 8,575 | 113,572 |
| Average Daily Volume (90 Day) | 6,827 | 50,263 |
| Shares Outstanding | 21.25M | 45.75M |
| Float Shares | 5.20M | 15.12M |
| % Held by Insiders | 0.76% | 0.67% |
| % Held by Institutions | 0.08% | 0.17% |
Dividend Analysis & Yield Comparison: Abbott India vs Pfizer
| Metric | ABBOTINDIA | PFIZER |
|---|---|---|
| Last 12-Month Dividend | ₹475.00 | ₹70.00 |
| Last 12-Month Dividend Yield | 1.41% | 1.27% |
| 3-Year Avg Annual Dividend | ₹451.67 | ₹46.67 |
| 3-Year Avg Dividend Yield | 0.99% | 0.58% |
| 3-Year Total Dividends | ₹1,355.00 | ₹140.00 |
| Ex-Dividend Date | Jul 25, 2025 | Jul 09, 2025 |